Josee Zijlstra

PROF.DR., (Principal Investigator)

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

89Zr-immuno-PET: Towards a clinical tool to guide antibody-based therapy in cancer

Jauw, YWS., 19 Sep 2019

Research output: ThesisResearch VU University Amsterdam, graduation VU University AmsterdamAcademic

89 Zr-immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo

Jauw, Y., o'Donoghue, J., Zijlstra, J., Hoekstra, O., Menke-van der Houven van Oordt, C. W., Morschhauser, F., Carrasquillo, J., Zweegman, S., Pandit-Taskar, N., Lammertsma, A., van Dongen, G., Boellaard, R., Weber, W. & Huisman, M., 30 May 2019, In : Journal of Nuclear Medicine. p. jnumed.118.224568

Research output: Contribution to journalArticleAcademicpeer-review

Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis

Jauw, Y. W. S., Bensch, F., Brouwers, A. H., Hoekstra, O. S., Zijlstra, J. M., Pieplenbosch, S., Schröder, C. P., Zweegman, S., van Dongen, G. A. M. S., Menke-van der Houven van Oordt, C. W., de Vries, E. G. E., de Vet, H. C. W., Boellaard, R. & Huisman, M. C., 1 Aug 2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 46, 9, p. 1840-1849

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

Rigter, L. S., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Zijlstra, J. M., van Imhoff, G. W., Poortmans, P. M. P., Beijert, M., Lugtenburg, P. J., Visser, O., Snaebjornsson, P., van Eggermond, A. M., Aleman, B. M. P., van Leeuwen, F. E. & van Leerdam, M. E., 2019, In : Cancer Medicine. 8, 1, p. 190-199 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 2019, In : Haematologica. 104, 4, p. e151-e153

Research output: Contribution to journalComment/Letter to the editorAcademic

Open Access